Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(2.28)
# 2,748
Out of 5,031 analysts
123
Total ratings
49.32%
Success rate
-3.98%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XRAY DENTSPLY SIRONA | Maintains: In-Line | $17 → $13 | $12.51 | +3.92% | 8 | Oct 8, 2025 | |
| TDOC Teladoc Health | Maintains: In-Line | $8 → $9 | $8.53 | +5.51% | 5 | Oct 8, 2025 | |
| IQV IQVIA Holdings | Maintains: Outperform | $220 → $240 | $204.55 | +17.33% | 7 | Oct 8, 2025 | |
| HNGE Hinge Health | Maintains: Outperform | $60 → $65 | $49.28 | +31.90% | 2 | Oct 8, 2025 | |
| HCAT Health Catalyst | Maintains: In-Line | $4 → $3 | $3.05 | -1.64% | 9 | Oct 8, 2025 | |
| FTRE Fortrea Holdings | Maintains: In-Line | $7 → $11 | $9.45 | +16.40% | 10 | Oct 8, 2025 | |
| DOCS Doximity | Maintains: Outperform | $75 → $81 | $67.57 | +19.88% | 9 | Oct 8, 2025 | |
| DGX Quest Diagnostics | Maintains: In-Line | $185 → $190 | $189.51 | +0.26% | 4 | Oct 8, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $170 → $160 | $130.45 | +22.65% | 14 | Oct 8, 2025 | |
| LH Labcorp Holdings | Maintains: Outperform | $300 → $305 | $285.94 | +6.67% | 7 | Oct 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $800 → $825 | $786.00 | +4.96% | 7 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $83 | $62.98 | +31.79% | 1 | Aug 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $190 | $156.41 | +21.48% | 9 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $28 | $25.53 | +9.67% | 4 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $23 | $19.96 | +15.23% | 4 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $5 → $3 | $0.96 | +212.53% | 5 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $65 | $82.52 | -21.23% | 6 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $36 | $36.98 | -2.65% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $4.40 | +496.59% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $4.77 | +214.47% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $1.84 | +497.83% | 2 | Jan 4, 2022 |
DENTSPLY SIRONA
Oct 8, 2025
Maintains: In-Line
Price Target: $17 → $13
Current: $12.51
Upside: +3.92%
Teladoc Health
Oct 8, 2025
Maintains: In-Line
Price Target: $8 → $9
Current: $8.53
Upside: +5.51%
IQVIA Holdings
Oct 8, 2025
Maintains: Outperform
Price Target: $220 → $240
Current: $204.55
Upside: +17.33%
Hinge Health
Oct 8, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $49.28
Upside: +31.90%
Health Catalyst
Oct 8, 2025
Maintains: In-Line
Price Target: $4 → $3
Current: $3.05
Upside: -1.64%
Fortrea Holdings
Oct 8, 2025
Maintains: In-Line
Price Target: $7 → $11
Current: $9.45
Upside: +16.40%
Doximity
Oct 8, 2025
Maintains: Outperform
Price Target: $75 → $81
Current: $67.57
Upside: +19.88%
Quest Diagnostics
Oct 8, 2025
Maintains: In-Line
Price Target: $185 → $190
Current: $189.51
Upside: +0.26%
Align Technology
Oct 8, 2025
Maintains: Outperform
Price Target: $170 → $160
Current: $130.45
Upside: +22.65%
Labcorp Holdings
Oct 3, 2025
Maintains: Outperform
Price Target: $300 → $305
Current: $285.94
Upside: +6.67%
Sep 24, 2025
Maintains: Outperform
Price Target: $800 → $825
Current: $786.00
Upside: +4.96%
Aug 26, 2025
Upgrades: Outperform
Price Target: $83
Current: $62.98
Upside: +31.79%
Aug 13, 2025
Maintains: Outperform
Price Target: $200 → $190
Current: $156.41
Upside: +21.48%
Jul 9, 2025
Maintains: Outperform
Price Target: $30 → $28
Current: $25.53
Upside: +9.67%
Jul 9, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $19.96
Upside: +15.23%
Jul 9, 2025
Maintains: In-Line
Price Target: $5 → $3
Current: $0.96
Upside: +212.53%
Jan 27, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $82.52
Upside: -21.23%
Nov 7, 2024
Maintains: Outperform
Price Target: $32 → $36
Current: $36.98
Upside: -2.65%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $4.40
Upside: +496.59%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $4.77
Upside: +214.47%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $1.84
Upside: +497.83%